MOSCOW, November 29. /TASS/. The Epivaccorona anti-coronavirus vaccine developed by Russia's Vector State Research Center of Virology and Biotechnology may be put into civil circulation in December, the Center's director, Rinat Maksyutov, said on Sunday.
"We have already manufactured 35,000 vaccine doses and plan that the output will be 50,000 doses by the yearend. Some 5,000 doses went to post-registration clinical tests and the rest will be put into civil circulation," he said at an online Science Bar Hopping festival. "We expect that a larger part will be put on the market in December."
According to Maksyutov, the first batch of vaccines that will be put into civil circulation is to be tested at the health ministry's institutions not earlier than December 7-8.
On July, 24, the Center received a Russian health ministry permit for clinical trials of its anti-coronavirus vaccine on volunteers. The first volunteer was inoculated on July 27. The final group of 20 volunteers was released from hospital on September 8. The vaccine's clinical trials were completed on September 30. Russian President Vladimir Putin said on October 14 that the Vector-developed vaccine had received registration. On November 16, the health ministry issued a permit for post-registration trials of the vaccine on volunteers older than 60 and a permit for tests on 3,000 volunteers aged from 18 to 60 was issued on November 18.
To date, 2,269,316 coronavirus cases have been confirmed in Russia, with 1,761,457 patients having recovered from the disease. Russia's latest data indicates 39,527 fatalities nationwide. Earlier, the Russian government set up an Internet hotline to keep the public updated on the coronavirus situation.